Quintiles, the US-based provider of biopharmaceutical-development and commercial-outsourcing services, has entered into a five-year strategic partnership to optimise the clinical development of pipeline products at Biogen Idec.
Under the agreement, a dedicated team from Quintiles will work with Biogen Idec on the design, planning and execution of the US company’s Phase II-IV clinical trials as well as selected Phase I studies.
Biogen Idec will also leverage Quintiles’ technology and systems across its growing portfolio of innovative therapies for neurodegenerative, haematologic and autoimmune diseases.
The collaboration will draw on expertise and experience from both organisations to maximise Biogen Idec’s clinical-development processes and boost efficiency, with an emphasis on transparency, quality, innovation and operational excellence.
New projects are already being initiated through the partnership, while several of Biogen Idec’s ongoing clinical studies are transitioning to the Quintiles team.
According to Tom Pike, chief executive officer of Quintiles, the relationship “exemplifies the ongoing evolution of drug-development collaboration and reinforces the increasingly important role that biopharmaceutical service providers such as Quintiles have in these efforts”.